Quarterly Results June 30, 2026

The General Manager-Listing Corporate Relationship Department BSE Limited, Ground Floor, P.J. Towers, Dalal Street, Mumbai-400001 Scrip Code: 524632 Dear Sir/Madam, Sub: Outcome of the meeting of the Board of Directors held on Wednesday, 12" August, 2026 Ref: Regulation 30 & 33 of the Securities and Exchange Board ofI ndia (Listing Obligation and Disclosure Requirement) Regulation, 2015 Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at their meeting held today i.e. 12 August, 2026 at the Registered Office of the Company inter-alia has, considered and approved the following: - Un-Audited Financial Results of the Company for the First Quarter ended June 30, 2026, along with the Auditors’ Limited Review Reports in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations. These results have been duly reviewed by the Audit Committee and audited by M/s Shah Sanghvi and Associates, Chartered Accountants (FRN:140107W), Statutory Auditors of the Company. (The copies of the aforesaid Standalone and consolidated Financial Results along with the limited review report are enclosed herewith.) Reviewed other Business of the Company. The Board Meeting commenced at 1:30 p.m. and concluded at 2:30 p.m. You are requested to take the above information on records and disseminate the same on your respective websites. Thanking you, Yours faithfully Company Secretarfand’co ¥ iance officer Membership Number: A80894 Encl.: a/a CIN : L24231GJ1993PLC019079 Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317 Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com SHUKRA PHARMACEUTICALS LIMITED CIN: 1242316)1993PLCO19079 3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054 Email : info@shukrapharmaceuticals.com STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (All amounts in X Lakhs, Unless Otherwise Stated) QUARTER ENDED 'YEAR ENDED sr. Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 No. (Unaudited) (Audited) (Unaudited) (Audited) 1_[income from Operations 1[Revenue from Operations 2,352.23 630.29 539.11 567061 (a) Net Sales/ Income from Operations 2,352.23 630.29 539.11 5,670.61 [Other Income 53.97 94.72 110.97 45848 | Total Income from Operations (I+11) 2,406.20 725.01 650.08 6,129.10 2_|Expenses (2) Cost of materials consumed 125.46 669.03 _(124385) 1,945.02 (b) Purchase of Stock-in Trade - - - - :;)‘(r::::gn in inventories of finished goods, and work-in-progress and stock (279.00) (75.00) 201.88 (360.12) (d) Employee Benefit Expenses 24153 37.18 182.49 70372 (e) Finance Cost 22,95 25.83 2681 10930 (7) Depreciation & Amortisation Expenses 107.40 100.75 78.72 34427 (g) Other Expenses 14363 (69.53) 147.71 509.62 Total Expenses 38197 688.25 51278 325181 3_[Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2) 2,024.23 3675 137.30 2,877.29 4 _[Exceptional Items = = = = 5_[Profit/ (Loss) before Extra ordinary items and Tax (3-4) 2,024.23 36.75 13730 2,877.29 6| Extra ordinary items - - - - 7_|Net Profit / (Loss) from Ordinary Activities before Tax(5-6) 2,024.23 36.75 137.30 2,877.29 8 _|Tax Expenses | Current Tax 516.82 44263 4059 73227 I1. Deferred Tax 443 (233.21) (6.24)] (221.93) I, Tax of Earlier Year - (0.00) - 16215 9 _|Net Profit / (Loss) for the Period (7-8) 1,502.98 (172.67) 10296 2,20.79 10_[Other Comprehensive Income (net off Tax) Remeasurement of defined benefit plans - (8.72) - (8.72) 11 |Total Comprehensive Income for the period (9+10) 1,502.98 (181.39) 102.96 2,196.08 12_|Paid up Equity Share Capital 4,378.79 4,378.79 4,378.79 4,378.79 13_|Face Value of Equity Shares 100 1.00 1.00 100 14_[Earnings per Share (ofX 1/-each ) : (a) Basic-x[ 034 (0.04) 0.02 0.50 (b) Diluted-X 034 (0.04) 0.02 0.50 NOTES: 1. The above Unaudited Standalone Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at ts meeting held on August 12, 2026. 2. The Unaudited Standalone Financial Results are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to confirm with the Unaudited Standalone Financial Results. 3. The Unaudited Standalone Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, wherethe Shares of the Company are listed. 4. During the quarter ended June 30, 2026, the Company received 0 investor complaints. Consequently, no investor complaint was pending as on June 30, 2026. 5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary. 6. The Company is operating in two segments, namely “Shukra Pharmaceutical” and “Shukra MedTech”; accordingly, the above results pertain to both segments. Further, the segment name “Shukra MedTech” s effective from October 1, 2025 onwards. For and on behalf of the Board of Directors of SHUKRA PHARMACEUTICALS LIMITED Dakshesh Shah Place: Ahmedabad Managing Director Date: August 12, 2026 DIN : 00561666 CIN : L24231GJ1993PLC019079 Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317 Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com SHUKRA PHARM/ IACEU'I TICALS liMl':rén CIN: L24231GJ1993PLC019079 3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054 Email : info@shukrapharmaceuticals.com STANDALONE SEGMENT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2026 (Rs. in Lakhs) QUARTER ENDED YEAR ENDED Particulars 30062026 | 31-03-206 | 30-06-2025 | 31-03-2026 (Unaudited) | (Audited) | (Unaudited) | (Audited) 01. Segment Revenue Net Sales/income from each segment (i) Pharamaceutical segment 2,406.20 72501 650.08 6,129.10 (ii) Medtech segment - - - - Total Segment Revenue| 2,406.20 725.01 650.08 6,129.10 Less: Inter Segment Revenue - - - - Revenue From Operation| 2,406.20 725.01 650.08 6,129.10 02. Segment Results Profit/Loss before tax and interest from each segment (i) Pharamaceutical segment 2,067.18) 6258 164.11 2,986.59 (ii) Medtech segment - - - - Profit/Loss before tax and interest from each segment| 2,067.18 62.58 164.11 2,986.59 Add/Less : i) Finance Cost 4295 2583 2681 109.30 i) Other Unallocable Expenditure net off unallocable income - - - - Profit Before Tax] 2,024.23 36.75 137.30 2,877.29 03. Segment Assets (i) Pharamaceutical segment 2281 778 2911 2,094.53 (ii) Medtech segment 0.23] 1,154.94 - 1,268.49 Total Segment Assets| 43.04] 1,162.72 29.11 3,363.01 Unallocable Assets| - i g ] Net Segment Assets| 43.04 1,162.72 29.11 3,363.01 04. Segment Liabilities (i) Pharamaceutical segment 2,225.84 1,410.71 431.22 2,308.29 (ii) Medtech segment - - - - Total Segment Liabilties| 2,225.84 1,410.71 431.22 2,308.29 Unallocable Liabilities| - B | - Net Segment Liabilities| 2,225.84 1,410.71 431.22 2,308.29 05. Capital Employed (Segment Assets- Segment Liabilities) (i) Pharamaceutical segment (2,183.03) (1,402.93) (402.11)| (213.76) (ii) Medtech segment 0.23 1,154.94 - 1,268.49 Note: 1.The Company is operating in two segments, namely “Shukra Pharmaceutical” and “Shukra MedTech”; accordingly, the above results pertain to both segments. Further, the segment name “Shukra MedTec [Showing first 8,000 characters — download PDF for full document]